|
 The study met its primary endpoint and key secondary endpoints,
demonstrating the drug's superiority over a placebo in achieving
remission of the gastrointestinal disease at week 26, the company
said in a statement.
"The proportion of patients meeting the primary endpoint was
significantly greater in the RHB-104 group compared to placebo,"
RedHill said.
Patients treated with RHB-104 also experienced a statistically
significant benefit in achieving early remission at week 16 and in
durable remission over weeks 16-52.
RHB-104 was found to be generally safe and well tolerated, said the
company, which is focused on proprietary drugs for gastrointestinal
diseases.
"Many patients with Crohn’s disease do not achieve remission on
current standard-of-care therapies, which are accompanied with poor
side effects," said David Graham, lead investigator of the Phase III
study.
"RHB-104 appears to have the potential to become a promising, new,
orally administered therapy for this important debilitating
disease."
RHB-104 is a proprietary, antibiotic combination therapy that is
based on the hypothesis that Crohn’s disease is
caused by a bacterial infection in susceptible patients called
mycobacterium avium subspecies paratuberculosis (MAP).
[to top of second column] |
The Phase III study of RHB-104 enrolled 331 subjects with moderately
to severely active Crohn’s disease in the United State, Canada,
Europe, Australia, New Zealand and Israel.
An extension Phase III study is ongoing to evaluate RHB-104 in
patients who remain with active Crohn’s disease after 26 weeks of
therapy in the first Phase III trial.
Additional clinical studies will most likely be required to support
filing a new drug application.
"RedHill will meet with key opinion leaders and the U.S. Food and
Drug Administration to present the data package and discuss the
development path to potential approval and will continue discussions
with potential partners for RHB-104," the company said.
Approximately 1.5 million people worldwide have been diagnosed with
Crohn's disease. Global sales of Crohn’s disease therapies are
estimated to exceed $10 billion in 2018, RedHill said, citing data
from research firm GlobalData.
($1 = 3.6622 shekels)
(Reporting by Tova Cohen; editing by Jason Neely)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
